Biểu đồ giá cổ phiếu ATAI
ATAI Giá
AtaiBeckley Inc
$4.12
-4.84%
$-0.2
Khi đóng cửa: Apr 29, 16:00:00 GMT-4
$4.1
-0.46%
$-0.01
Phiên sau giờ: Apr 29, 17:35:08 GMT-4
Quay lại
AtaiBeckley Inc (ATAI) Giá
Thống kê chính
Giá đóng cửa trước
$4.33
Giá mở cửa
$4.31
Phạm vi ngày
$4.05 - $4.35
Phạm vi 52 tuần
$1.29 - $6.75
Khối lượng
3.5M
Khối lượng trung bình
4.9M
Tỷ suất cổ tức
--
EPS (TTM)
-2.30
Vốn hóa thị trường
$1.4B
ATAI là gì?
Atai Beckley, Inc. is a clinical-stage biopharmaceutical company focused on developing effective, rapid-acting, and convenient mental health treatments. The company is headquartered in New York City, New York and currently employs 99 full-time employees. The company went IPO on 2021-06-18. The Company’s pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 (R-MDMA HCI) for social anxiety disorder. The firm is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for opioid use disorder and TRD. BPL-003 is a proprietary synthetic intranasal formulation of mebufotenin benzoate being developed as a potential treatment for people living with TRD. VLS-01 is a proprietary oral transmucosal film formulation of N,N-Dimethyltryptamine (DMT) being developed as a potential treatment for people living with TRD. EMP-01 is an oral formulation of R-MDMA, being developed as a potential treatment for people living with social anxiety disorder.
